Clinical trials: Atrium; Flutter
Atrial Fibrillation
Study of RSD1235-SR for the Prevention of Atrial Fibrillation/Atrial Flutter Recurrence
This study is designed to evaluate the safety, tolerability and preliminary efficacy of vernakalant (oral) in subjects with sustained atrial fibrillation of greater than 72 hours and less than 6 months duration
- Trial name
- NCT00267930
- Testing
- Vernakalant (oral)
- Where
- 22 sites in United States, Canada and 2 more
- Volunteers
- 221 people
- Sponsor
- Advanz Pharma